Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar-Apr;23(1):66-76.

CROI 2015: Highlights of Viral Hepatitis Therapy

Anne F Luetkemeyer  1 , David L Wyles  2
Affiliations

CROI 2015: Highlights of Viral Hepatitis Therapy

Anne F Luetkemeyer et al. Top Antivir Med. 2015 Mar-Apr.

Abstract

High cure rates with all-oral regimens for patients with HIV/hepatitis C virus (HCV) coinfection were a highlight of the 2015 Conference on Retroviruses and Opportunistic Infections. Twelve weeks of sofosbuvir and daclatasvir led to sustained virologic response (SVR) rates of 96% in treatment-naive and 98% in treatment-experienced HCV genotype 1-infected patients. Twelve weeks of sofosbuvir plus ledipasvir had similar results, with SVR rates of 95% in treatment-naive and 96% in treatment-experienced patients. Patients with cirrhosis were included in both trials and attained SVR rates of 92% to 94%. Real-world performance of sofosbuvir and simeprevir resulted in SVR rates similar to those attained in clinical trials. Identifying HCV infection, linking patients to care, reducing barriers to drug access, and ensuring adherence will be key to realizing the enormous potential of high cure rates with interferon alfa-free therapies. Preventing reinfection after cure will be of particular importance in the HIV-infected population, which was highly impacted by reinfection rates of more than 20% during 5 years of follow-up in a meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Financial affiliations in the past 12 months: Dr Luetkemeyer has received grants awarded to her institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and Pfizer, Inc. Dr Wyles has received grants awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, and Merck & Co, Inc, and serves on an advisory board for Bristol-Myers Squibb.

References

    1. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; - PMC - PubMed
    1. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888. - PubMed
    1. Eley T, You X, Wang R, et al. Daclatasvir: overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs [Abstract 63]. HIV DART 2014 December 9-12, 2014; Key Biscayne, Florida.
    1. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 313(12):1223-1231. - PubMed
    1. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;369(7):678-679. - PubMed

Publication types

LinkOut - more resources